Drilldown: Medicines

None (1) · Calcium (carbonate, citrate, gluconate, chloride salts) (1) · Insulin aspart (1) · Insulin lispro (1) · Ivermectin (1) · Magnesium (oxide, citrate, sulfate, hydroxide, gluconate, chloride salts) (1)

Humalog, Admelog, Lyumjev (1) · Mag-Ox, Slow-Mag, MagCitrate, Milk of Magnesia (hydroxide); IV sulfate generic (1) · NovoLog, Fiasp (ultra-rapid), Trurapi (1) · Stromectol (oral, generic), Sklice (lice, topical), Soolantra (rosacea, topical 1%) (1) · Sunosi (1) · Tums, Caltrate, Os-Cal, Citracal; many generics (1)

hydroxide)]] (1) · Norepinephrine-dopamine reuptake inhibitor (NDRI) (1) · torsades)]] (1) · wake-promoting agent (1) · [[:Category:Antacids|Antacid (carbonate)]] (1) · [[:Category:Antacids|Antacid (hydroxide)]] (1) · [[:Category:Antiarrhythmics|Antiarrhythmic (IV sulfate (1) · [[:Category:Antiparasitics|Antiparasitic]] (1) · [[:Category:Calcium_supplements|Calcium supplement]] (1) · [[:Category:Electrolyte_replacements|Electrolyte replacement]] (2) · [[:Category:Insulins|Insulin]] (2) · [[:Category:Macrocyclic_lactones|Macrocyclic lactone (avermectin)]] (1) · [[:Category:Mealtime_insulins|Mealtime (bolus) insulin]] (2) · [[:Category:Osmotic_laxatives|Osmotic laxative (citrate (1) · [[:Category:Rapid-acting_insulins|Rapid-acting insulin analog]] (2)

None (3) · Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines, pure reuptake inhibition. (1) · '"`UNIQ--vote-00000584-QINU`"' Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio. Ultra-rapid formulations (Lyumjev) add treprostinil and citrate to accelerate absorption further'"`UNIQ--ref-00000585-QINU`"'. (1) · '"`UNIQ--vote-00001302-QINU`"' Renally cleared; accumulation in advanced CKD can produce neuromuscular and cardiac depression. Hypomagnesemia frequently co-exists with hypokalemia and is often the reason refractory potassium loss does not correct until magnesium is repleted. (1)

Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA) (1) · '"`UNIQ--vote-00000586-QINU`"', '"`UNIQ--vote-00000587-QINU`"', '"`UNIQ--vote-00000588-QINU`"' (1) · '"`UNIQ--vote-000005EF-QINU`"', '"`UNIQ--vote-000005F0-QINU`"', '"`UNIQ--vote-000005F1-QINU`"' (1) · '"`UNIQ--vote-0000108C-QINU`"', '"`UNIQ--vote-0000108D-QINU`"', '"`UNIQ--vote-0000108E-QINU`"', '"`UNIQ--vote-0000108F-QINU`"', '"`UNIQ--vote-00001090-QINU`"', '"`UNIQ--vote-00001091-QINU`"' (1) · '"`UNIQ--vote-000012B7-QINU`"', '"`UNIQ--vote-000012B8-QINU`"', '"`UNIQ--vote-000012B9-QINU`"', '"`UNIQ--vote-000012BA-QINU`"', '"`UNIQ--vote-000012BB-QINU`"' (1) · '"`UNIQ--vote-00001303-QINU`"', '"`UNIQ--vote-00001304-QINU`"', '"`UNIQ--vote-00001305-QINU`"', '"`UNIQ--vote-00001306-QINU`"', '"`UNIQ--vote-00001307-QINU`"', '"`UNIQ--vote-00001308-QINU`"', '"`UNIQ--vote-00001309-QINU`"' (1)

Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate. (1) · Oral: 1000-1500 mg elemental calcium/day in divided doses for supplementation; IV gluconate 1 g (4.65 mEq) over 5-10 min for hyperkalemia or symptomatic hypocalcemia (1) · Replacement oxide 400-800 mg/d in divided doses (high diarrhea rate); citrate 200-400 mg/d (better tolerated, better absorbed); IV sulfate 1-2 g over 5-60 minutes for hypomagnesemia or torsades; eclampsia 4-6 g IV loading then 1-2 g/h (1) · SC 4-6 units (or 1 unit per 10-15 g carbs) at meals; titrate to postprandial glucose (1) · SC 4-6 units (or 1 unit per 10-15 g carbs) at meals; titrate to postprandial glucose. Typical total daily dose 0.5-1 U/kg/d split between basal and prandial coverage in T1DM (1) · Strongyloides 200 mcg/kg PO single dose; scabies 200 mcg/kg PO repeated at 7-14 days; onchocerciasis 150 mcg/kg q6-12 months (1)

100 U/mL (Humalog, Admelog, Lyumjev) vials, pens, cartridges; 200 U/mL Humalog KwikPen (1) · 100 U/mL (NovoLog, Fiasp) vials, pens, cartridges (1) · 3 mg tablets (Stromectol); 0.5% topical lotion (Sklice); 1% topical cream (Soolantra) (1) · 75 mg, 150 mg tablets (1) · Carbonate 200, 400, 500, 600 mg elemental tablets and chewables; citrate 200, 250, 315 mg elemental; gluconate 1 g (94 mg elemental, 4.65 mEq) IV; chloride 1 g (270 mg elemental, 13.6 mEq) IV (1) · Oxide 400, 500 mg tablets (240, 300 mg elemental); citrate 100, 150, 200 mg tablets; hydroxide oral suspension 400 mg/5 mL; sulfate IV 500 mg/mL ampules (1)

150 mg/d (1) · Indication-specific; renal clearance limits tolerable cumulative dosing (1) · Single 200-400 mcg/kg per dose for systemic indications (1) · Titrated to glucose; no fixed maximum (2) · ~2500 mg elemental/d combined diet + supplements (chronic; UL) (1)

insulin pumps (2) · IV (2) · IV (continuous infusion for DKA) (1) · IV (gluconate or chloride for acute use) (1) · Oral (4) · Subcutaneous (2) · topical (1)

Acute: minutes (IV); chronic: bone effect over months (1) · Hours to days (1) · Oral: hours; IV: minutes (1) · SC: 5-15 minutes (Fiasp 2.5 minutes earlier on average) (1) · SC: 5-15 minutes; ultra-rapid Lyumjev faster (1) · ~30-60 min (1)

None · 24 hours · 4-6 hours · 12 hours · 6-8 hours · Daily dosing · 8-12 hours · 12-24 hours · Hours · Hours per application · 24 hours (HS dosing) · 24 hours (once-daily dosing) · 24 h · N/A · N/A (replacement) · Variable · ~7-8 hours · 3-5 hours · 4-6 hours (IR); 24 hours (ER) · 6-12 hours

Other values:

Search

Not meaningfully described (electrolyte) (1) · Not meaningfully described (electrolyte; renally cleared) (1) · ~1 hour SC'"`UNIQ--ref-00000589-QINU`"' (1) · ~16-18 hours'"`UNIQ--ref-00001092-QINU`"' (1) · ~7.1 hours (1) · ~80 minutes SC'"`UNIQ--ref-000005F2-QINU`"' (1)

Carbonate ~30-40% (best with food and acid); citrate ~24% (absorbable without acid; preferred in achlorhydria, PPI use, post-bariatric) (1) · Highly salt-dependent: citrate ~25-30%; oxide ~4% (limited and causes osmotic diarrhea); chloride ~12% (1) · ~100% from subcutaneous depot (2) · ~60% (oral; substantially increased with high-fat meal)'"`UNIQ--ref-00001093-QINU`"' (1) · ~95% (1)

Insulin is the preferred glucose-lowering therapy in pregnancy; aspart is widely used.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Insulin is the preferred glucose-lowering therapy in pregnancy; lispro is widely used.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · IV sulfate is the cornerstone of eclampsia/preeclampsia management; oral replacement also safe.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Limited data; pregnancy exposure registry available (1) · Limited data; risk-benefit case by case; pregnancy is not a strict contraindication in WHO mass drug administration programs.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Routinely supplemented in pregnancy; needs higher in pregnancy and lactation.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

OTC (oral salts) and [[USLegal:Prescription only|Rx-only]] (IV) in US (1) · OTC (oral supplements) and [[USLegal:Prescription only|Rx-only]] (IV) in US (1) · Rx, Schedule IV (US) (1) · [[USLegal:Prescription only|Rx-only]] in US (1) · [[USLegal:Prescription only|Rx-only]] in US (some OTC formulations exist) (1) · [[USLegal:Prescription only|Rx-only]] in US (the veterinary preparations are not for human use) (1)